Introduction: A hormonal role in NSCLC development is well documented. We previously showed that the aromatase inhibitor (AI) anastrozole decreased development of tobacco carcinogen-induced lung tumors in a murine lung cancer prevention model and that aromatase and estrogen receptor were expressed in pulmonary inflammatory cells.
Methods:
We utilized a tobacco carcinogen-induced lung tumor mouse model by treatment with 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK), to determine whether an AI combined with nonsteroidal antiinflammatory drugs results in greater lung tumor prevention effects compared to single-agent treatment.
Results: Combination of anastrozole (0.1 mg/kg/d) with aspirin (25 mg/kg/d) after NNK exposure resulted in significantly fewer and smaller lung tumors than did singleagent treatments and was accompanied by maximum decreases in circulating b-estradiol (E2) and interleukin-6, tumor-infiltrating macrophages, and tumoral Ki67, phospho-mitogen-activated protein kinase, phospho-signal transducer and activator of transcription 3, and interleukin-17A expression. Preneoplasia arising after combination treatment showed the lowest Sox-2 expression, suggesting an inhibitory effect on proliferative capacity in the airways by blocking both E2 and inflammation. Anastrozole combined with ibuprofen instead of aspirin also showed enhanced antitumor effects. Moreover, male mice treated with NNK that received E2 in their drinking water showed greater levels of pulmonary macrophages and inflammatory markers than did the control, confirming an E2 effect on inflammation in the microenvironment.
Conclusions:
Our results suggest a benefit to joint targeting of the estrogen and inflammatory pathways for NSCLC prevention. Combining AIs with nonsteroidal anti-inflammatory drugs reduces circulating E2, proinflammatory cytokines, and macrophage recruitment in the lung microenvironment after tobacco exposure. This strategy could be particularly effective in women who have underlying pulmonary inflammatory diseases.
Introduction
Lung cancer is the number one cause of cancer death worldwide. Despite advances in therapeutic modalities, the 5-year survival for patients with lung cancer is a *Corresponding author.
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dismal 18%, 1 demonstrating the continued need to develop novel therapeutic and preventive approaches for lung cancer. Preclinical and epidemiological studies support a role for estrogenic pathways in driving lung cancer progression. [2] [3] [4] [5] [6] [7] [8] [9] [10] Expression of estrogen receptors (ERs), progesterone receptors, and/or aromatase, a key enzyme in estrogen biosynthesis, is frequently found in NSCLCs, [2] [3] [4] 7 and high expression of tissue aromatase is a poor prognostic marker in postmenopausal women with NSCLC. 5 Preclinically, b-estradiol (E2) induced proliferation in NSCLC in vitro and in vivo, 2, 6, 8 and estrogen receptor b (ERb) was found to be the predominant ER isoform expressed and functional in lung cancer. 3, 8 We and others have demonstrated that the antiestrogen fulvestrant and aromatase inhibitors (AIs) partially inhibit lung tumor growth 6, 11, 12 and prevent lung tumorigenesis in murine models, 13 suggesting that repurposing endocrine therapies developed for ER-positive breast cancer may be effective for prevention or treatment of ER-positive lung cancer.
Estrogen activity on nontumor cells within the tumor microenvironment is becoming increasingly recognized as playing an important role in tumor progression. We have shown that aromatase is expressed not only in human lung epithelial cells 2, 3 but also in lung macrophages 13 and that estrogen is present locally at sites of pulmonary inflammation. 13 Toniolo et al. recently demonstrated that the protumor M2 macrophage phenotype is promoted by E2, 14 and both macrophages and lymphocytes are known to express ERs. 15 This suggests that inflammation triggered by tobacco exposure in the lungs includes upregulation of an autocrine estrogen signaling loop in tumor-infiltrating immune cells. Estrogen signaling through ER-positive myeloidderived suppressor cells has recently been demonstrated in ovarian tumors; the immunosuppressive action of myeloid-derived suppressor cells induced by E2 may thus contribute to malignant progression. 16 Together, these data suggest that inflammatory cells that infiltrate the lungs in response to tobacco carcinogens may be an important source of estrogen synthesis and/or estrogen response, starting early in the carcinogenesis process. This enhanced E2-driven protumorigenic immune phenotype combined with increased local E2 production may stimulate proliferation within the lung epithelial compartment, contributing to lung cancer progression.
In this study, we evaluated the combined effects of AIs and NSAIDs on lung tumor number and size and explored the link between inflammatory biomarkers, macrophage recruitment in the lung microenvironment, and estrogen signaling by using a tobacco carcinogen-induced lung tumorigenesis murine model. Epidemiological studies have shown that use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen is associated with a decreased risk for lung cancer. [17] [18] [19] A recent meta-analysis confirmed a protective effect of aspirin use on lung cancer risk, with a reported relative risk of 0.87. 20 We show that an AI combined with an anti-inflammatory agent prevents tumor development after carcinogen exposure, more so than each single-agent treatment, in ovariectomized female mice. These mice are a model of ex-smoking postmenopausal women who could be eligible to use this treatment for chemoprevention. Our results also suggest that inhibiting tissue aromatase activity with an AI and reducing inflammation by means of an NSAID may be an effective strategy to reduce E2, proinflammatory cytokines, and macrophage recruitment, magnifying inhibition of the proliferative and signaling effects of E2. Moreover, we demonstrate that E2 treatment given during carcinogen exposure had an opposite proinflammatory effect in murine lungs, including increasing pulmonary macrophage numbers and producing higher inflammatory markers, compared to treatment with vehicle control. Together, our results strongly suggest that a combined AI and NSAID prevention strategy could be effective among the tobaccoexposed population, particularly in women who have underlying pulmonary inflammatory diseases such as chronic obstructive pulmonary disease.
Methods

Mouse Models
Female ovariectomized FVB/N mice (6 weeks of age) were exposed to the tobacco carcinogen 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK) (3 mg per intraperitoneal injection twice per week) for 4 weeks. Mice received subcutaneous supplementation with 0.1 mg androstenedione, the substrate for aromatase, three times per week for the entire course of the experiment. We utilized this postmenopausal model previously to evaluate the antitumor effects of anastrozole and fulvestrant. 13 Additionally, this model was chosen because AIs are contraindicated for use in premenopausal women and men. Each of the four treatment groups started with 12 to 14 mice on the basis of power calculations that assumed at least a 50% reduction in tumor number between treatment groups. Drug treatments were initiated 5 weeks after the final NNK injection to allow for lung preneoplasia development. This model mimics events that are often present in lungs of exsmokers. Anastrozole (0.1 mg/kg orally [n ¼ 12]), aspirin (dissolved in water [2.5 mg/mL] and administered at 25 mg/kg orally [n ¼ 12]), the combination of anastrozole with aspirin (n ¼ 14) or vehicle control (n ¼ 12) was administered 5 times per week for 8 weeks. In a separate experiment, ibuprofen (25 mg/kg orally) was substituted for aspirin treatment with use of the same protocol (see the animal numbers in Supplementary Table 1) . NSAID dosing corresponds to a dose of 150 mg daily for humans when using the body surface area normalization method. 21 Additionally, a short-term 2-week treatment exposure experiment was performed to evaluate cytokine expression in the lungs and blood before tumor formation. We also utilized an E2 exposure mouse model whereby male mice (chosen for this setting to minimize the effects of circulating E2 found in females) received NNK (3 mg per intraperitoneal injection twice per week) for 4 weeks and were simultaneously administered E2 (2 mM) or placebo control in the drinking water as described. 22 Mice were humanely killed after 8 weeks of treatment for AI and NSAID studies or after 4 weeks for E2 studies followed by formalin-inflation of lungs under 25 cm intraalveolar pressure and collection of blood. Surface lung tumors were counted under a dissecting microscope and tumor size (defined as surface area in mm 
E2 Enzyme-Linked Immunosorbent Assay
Blood was collected before the initiation of experimental treatment from the saphenous vein and at the end of treatment by cardiac puncture, processed for serum, and stored at -80 C. E2 (pg/mL) was measured in duplicate by using the Cayman Estradiol Enzyme-Linked Immunosorbent Assay Kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer's instructions.
Blood and Lung Tissue Cytokine Analysis
Serum levels of the following markers were measured in duplicate by using a customized mouse U-PLEX Biomarker kit (Meso Scale Discovery, Rockville, MD): interleukin-1b (IL-1b), IL-6, Il-10, IL-12/IL-23p40, IL-17A, IL-23, tumor necrosis factor-a, vascular endothelial growth factor A (VEGF-A), and interferon gamma. Results are reported in pg/mL.
Immunohistochemistry
Lungs were fixed in 10% formalin, paraffin-embedded, sliced, and mounted on slides. Slides were stained with hematoxylin and eosin. Sections were evaluated for Ki67, phospho-mitogen-activated protein kinase (P-MAPK), phospho-signal transducer and activator of transcription 3 (P-STAT3), F4/80, IL-17A, SRY-box 2 (Sox-2), phosphonuclear factor kappa light-chain enhancer of activated B cells (P-NFkB), and vascular endothelial growth factor (VEGF) expression in bronchial epithelium, preneoplastic areas, or tumor areas. Sections were incubated with primary antibodies overnight in a humidified chamber at 4 C with the following antibodies: Ki67 (Abcam, Cambridge, MA) (1:50), P-MAPK (Cell Signaling Technology, Danvers, MA) (1:400), P-STAT3 (Cell Signaling Technology) (1:400), F4/80 (AbD Serotec, Kidlington UK) (1:100), IL-17A (Abcam) (1:500), Sox-2 (Abcam) (1:1000), phospho-NFkB (P-NFkB) (Abcam) (1:200), or VEGF (Abcam) (1:200). Positive and negative controls were included for each marker. Bright field images were captured by using a Leica DMI 3000B scope and LASv4.7 software (Leica Biosystems, Nusslock, Germany). IL-17A, Sox-2, P-NFkB, and VEGF staining was graded as low (<30% positive cells per field), moderate (30%-60% positive cells per field), or high (>60% positive cells per field). Ki67 cell proliferation index was quantitated as the number of positive cells per field divided by the total number of tumor cells per field. For P-MAPK and P-STAT3 quantitation, the numbers of positive cells per field were counted. Tumor-infiltrating macrophages (F4/80 staining) were quantitated as the number of positive cells per field.
Statistical Analysis
Poisson regression was used to assess whether there was a significant relationship between treatment group and number of tumors per mouse. Mixed effects models were used to determine whether there was a significant relationship between treatment group and logtransformed tumor size, excluding mice in which tumors did not form. Group differences in Ki67 proliferation index, macrophage numbers, and blood/tumor marker quantitation were analyzed by Kruskal-Wallis and Mann-Whitney tests. For pretreatment versus posttreatment blood marker changes, Wilcoxon signed rank tests were used. Group differences in categorized immunohistochemistry (IHC) measures were analyzed by chi-square tests of independence. For antigens that showed significance by the chi-square test, individual Fisher's exact tests were performed to determine significant differences for each condition compared with placebo and for combination treatments compared with single treatments. All statistical tests were two sided with the threshold for significance defined as p less than 0.05. Analyses were conducted with GraphPad PRISM (version 7, GraphPad Software, La Jolla, CA) or SAS v. 9.4 (SAS Institute Inc., Cary, NC).
Results
Combination of the AI Anastrozole with Aspirin Decreased Carcinogen-Induced Lung Tumor Formation and Tumor Size
We have previously shown that lung tumors and infiltrating pulmonary macrophages from the NNKinduced lung tumorigenesis murine model express aromatase and ERb. 13 Inflammatory responses resulting from tobacco carcinogen exposure could be a key estrogen source driving tumor formation, supporting the idea of estrogen acting as a promoter of lung cancer aggressiveness through the inflammatory process in the lung microenvironment. 13 Therefore, using the NNK lung tumor model, we tested whether targeting both the estrogen and inflammatory pathways with anastrozole (0.1 mg/kg) plus aspirin (25 mg/kg) would have a greater effect on lung tumorigenesis than that of anastrozole or aspirin alone.
The numbers of tumors for the four treatment groups of the anastrozole/aspirin experiment are summarized in Table 1 and Figure 1A . Compared with the tumor burden in the vehicle control group, which had an average of 5.8 tumors per animal, the tumor burden was 37% lower in the anastrozole group (3.7 tumors per animal [p ¼ 0.02]) and 34% lower in the aspirin group (3.8 tumors per animal [p ¼ 0.03]). When both anastrozole and aspirin were administered together (2.1 tumors per animal), the mean tumor burden was 42% lower than in the anastrozole group (p ¼ 0.02), 44% lower than in the aspirin group (p ¼ 0.01), and 63% lower than for vehicle control (p < 0.001).
We also observed a significant association between treatment group and lung tumor size (see Table 1 and Fig. 1B ). Tumors ranged in size from 0.15 mm 2 to 4.23 mm 2 , with the largest tumor in the vehicle control group and no tumor larger than 1.87 mm 2 in the combination group. Tumors in the anastrozole-and aspirin-alone groups were 27% (p ¼ 0.01) and 21% (p ¼ 0.04) smaller, respectively, than to those in the vehicle control group. Tumors in the combination treatment group were on average 20% smaller than in the anastrozole group (p ¼ 0.13), 26% smaller than in the aspirin group (p ¼ 0.05), and 41% smaller than in the vehicle control group (p < 0.001).
Circulating Serum E2 Was Lower with AI and Aspirin Treatment
Anastrozole is known to lower estrogen levels in postmenopausal women. In addition, studies analyzing sex hormone concentrations in postmenopausal women reported that regular users of aspirin and other analgesics have lower circulating estrogen levels than nonusers do, which could be a potential mechanism to lower their risk for hormone-associated cancers. 23, 24 We therefore investigated whether circulating E2 was decreased by NSAID use in our animal model and whether adding NSAIDs to anastrozole had a further effect on E2 reduction. We collected serum before the initiation of experimental treatments and again at the end of the experiment to measure changes in E2 levels in each mouse by treatment. We observed 26% (p ¼ 0.03) and 23% (p ¼ 0.04) average decreases in circulating E2 after 8 weeks of anastrozole and aspirin treatment, respectively, compared with the pretreatment levels ( Fig. 2A) . With combination treatment, a 45% decrease (p ¼ 0.002) in E2 was observed (see Fig. 2A ). No change in pretreatment versus posttreatment E2 levels in control-treated mice were observed.
Proinflammatory Cytokine IL-6 Is Decreased by AI and Aspirin Treatment
To evaluate the effects of circulating inflammatory cytokines by experimental treatment, we analyzed a panel of markers including IL-1b, IL-6, Il-10, IL-12, IL-17A, IL-23, tumor necrosis factor-a, VEGF-A, and interferon gamma in mouse serum collected at the end of treatment. We found significant differences between the four treatment groups for IL-6 only ( Fig. 2B ) (Kruskal-Wallis test p ¼ 0.001, results for the other markers not shown). The median circulating IL-6 levels were 107.7 pg/mL for the for the anastrozole and aspirin treatment groups, respectively (see Fig. 2B ). The median IL-6 level (42.6 pg/mL) was 60% lower for combination treatment (p ¼ 0.0004) than for treatment with vehicle control, but it did not differ significantly from that for single-agent treatments. Individual IL-6 values were highly variable, particularly in the control treatment group (range 53.3-641.3 pg/mL). Although the mouse with the largest tumor had the highest IL-6 value, overall total tumor burden did not correlate with that of the mice with more than 500 pg/mL IL-6. However, to rule out the possibility that changes in IL-6 could be due solely to tumor burden rather than to experimental treatment, we measured IL-6 in a separate short-term experiment before tumor formation. We measured pretreatment and 2-week posttreatment IL-6 levels and observed decreases in IL-6 levels in individual mice (n ¼ 3-4) after only 2 weeks of anastrozole or aspirin treatment (Fig. 2C) .
Cell Proliferation and MAPK and STAT3 Signaling Are Decreased in Tumors Arising after AI or Aspirin Treatment
To determine whether tumors that occurred in the AI or aspirin treatment groups were less proliferative, we analyzed Ki67-positive tumor cells in formalin-fixed, paraffin embedded (FFPE) lung tissue collected at the end of the experiment (Fig. 3) . (Fig. 3B) , which was reflective of their decreased tumor size in this experiment as well (Fig. 1B) . Moreover, tumors arising in mice that received the combination were significantly less proliferative than tumors arising from single-agent treatments based on Ki67 labeling (p < 0.05). The antiproliferative effects of anastrozole and aspirin alone or in combination were accompanied by decreased activation of the MAPK and STAT3 signaling pathways. In the same FFPE tissues, we measured P-MAPK-and P-STAT3-positive tumor cells by IHC (Fig. 3A) and observed 37% (p ¼ 0.03) and 27% (not significant) lower median P-MAPK positivity with anastrozole or aspirin alone and a 61% decrease with the combination (p ¼ 0.03) compared with the levels in the control (Fig. 3B) . Similarly for P-STAT3, we found 68% (p ¼ 0.03) and 78% (p ¼ 0.03) decreases with anastrozole or aspirin alone, respectively, and almost a complete reduction (95% [p ¼ 0.03]) with the combination compared with the levels with the control (Fig. 3B) .
Tumor-Associated Macrophage Infiltration Is Negatively Correlated with AI and Aspirin Treatment
Macrophage infiltration is a hallmark of chronic inflammation. We therefore investigated the number of tumor-infiltrating macrophages in FFPE lung tissues by F4/80 immunostaining (Fig. 3C) Figure 3D shows representative IL-17A immunostaining, and quantitation of low-, moderate-, and high-grade 
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Aromatase Inhibitors, NSAIDs, and Lung Cancerstaining is shown in Fig. 3E . A significant (p < 0.001) shift toward increased low-grade scoring and less highgrade scoring was found with single-agent treatments, with the highest frequency of low-grade scores in the combination treatment group compared with the control. For example, anastrozole, aspirin, and the combination had 12% (p < 0.01), 20% (p < 0.01), and 4% (p < 0.01) of fields with high-grade scores compared with 68% in the control group. Circulating IL-17A in this animal model was very low, with less than 10 pg/mL detected under all conditions (not shown).
Sox-2 and VEGF Are Decreased in Airway Preneoplasias by Treatment with AI and Aspirin
We previously reported that expression of the lung cancer stem cell marker Sox-2 was significantly increased in the lungs of mice exposed to estrogen and down-regulated by antiestrogens. 22 Next, we investigated the effect of AI and aspirin treatment on Sox-2 expression in normal bronchial epithelium and preneoplastic areas of mouse lungs from NNK-treated animals. This allowed for a determination of treatment effects on the cell compartments that give rise to tumors. FFPE lung tissues were used for IHC evaluation of Sox-2 after 8 weeks of control, anastrozole, aspirin, or combination treatment (Fig. 4A) . IHC staining from 25 microscopic fields per treatment group were scored as low, moderate, or high, and the distribution of scores was significantly different across all treatment groups compared to the distribution with placebo (p < 0.001) in both the bronchial epithelium and preneoplastic areas, with a shift toward lower IHC scores (Fig. 4B) . After treatment with aspirin, whereas Sox-2 scores were shifted toward more low-and less high-grade scores, this was not significantly modified in the normal bronchial epithelium or preneoplasias compared with after treatment with vehicle control. However, after anastrozole and combination treatment, there was a greater proportion of low Sox-2 scores (p < 0.05) in both normal bronchial epithelium and preneoplasias. In bronchial epithelium, the proportions of fields with a low score were 56% (14 of 25) for anastrozole treatment and 48% (12 of 25) for combination treatment, compared with only 12% (three of 25) for the control. Aspirin had a slightly greater proportion of low scores (16% [four of 25]). Similar results were found in preneoplasias, with 40% (nine of 25), 80% (20 of 25), and 76% (19 of 25) low-scoring fields in aspirin, anastrozole, and combination treatments, respectively, compared with only 16% (four of 25) in the control group. No fields with Sox-2 high scores were observed with anastrozole or combination treatment, and only two of 25 (8%) had high scores in the aspirin group compared with 24% (six of 25) in the control group. These results demonstrate lung stem cell marker reduction in murine airways by blocking of the estrogen or inflammatory pathways.
We also measured protein expression of the E2-responsive gene, VEGF-A. 25 VEGF-A is secreted by both tumors and macrophages in the tumor microenvironment. Using the same tissues and IHC low-high grade scoring system, we found no expression changes by experimental treatment in the bronchial epithelium (not shown). However in preneoplastic areas, VEGF expression was reduced by anastrozole (p < 0.01) and combination treatment (p < 0.05) but not by aspirin treatment, with a shift to more low-grade scoring and less high-grade scoring (see Fig. 4A and B) . For example, 45% of the fields had high scores in the vehicle control group, compared with 0%, 25%, and 23% for the anastrozole, aspirin, and combination treatment groups, respectively.
Ibuprofen Elicits Antitumorigenic Effects Similar to Those of Aspirin When Combined with Anastrozole
To determine whether the association between aspirin and decreased tumor burden was specific to aspirin or whether other NSAIDs could exert a similar antitumor effect, we evaluated the effect of the reversible COX inhibitor ibuprofen. Using the same NNK animal model, we examined the effect on lung tumor burden and size with anastrozole, ibuprofen, or the combination of the two agents compared to control. Similar to the results of the aspirin and anastrozole experiment, we observed a 36% to 37% decrease in mean tumor burden per mouse with single-agent anastrozole or ibuprofen compared with the burden in the control group and an 84% lower burden when both anastrozole and ibuprofen were administered together (p <0.001) (Supplementary Table 1 and Supplementary Fig. 1A ). Furthermore, mice that received both agents developed a 75% lower average number of lung tumors per mouse compared with the mice treated with anastrozole or ibuprofen as a single agent (p <0.001) (see Supplementary Fig. 1A) . Although we observed a strong decrease in tumor number with these treatments, there was no effect on tumor size (Supplementary Table 1 and Supplementary Fig. 1B) .
We also observed decreases in circulating IL-6 in the anastrozole and/or ibuprofen experiment. Either anastrozole or ibuprofen alone resulted in lower median IL-6 levels, whereas the combination significantly decreased the median level by 83% (p ¼ 0.008) compared with the control (Supplementary Fig. 2A ). Pretreatment and posttreatment 2-week treatment IL-6 effects were also observed (Supplemental Fig. 2B ). Ki67 proliferative effect by treatment was not as strong in the anastrozole/ ibuprofen experiment (data not shown) as in the anastrozole/ibuprofen experiment, which corresponded to the lack of significant tumor size differences. These results suggest that NSAIDs show enhancement of the protective effect of AI on the development of carcinogeninduced lung tumors and may reduce tumor size.
Estrogen Triggers an Immune Inflammatory Response in the NNK Carcinogen-Treated Mouse Model
To further evaluate the effect of estrogen signaling on inflammation, we used FFPE lung tissue as well as blood and bronchioalveolar lavage fluid from male mice treated with NNK that also received E2 in their drinking water for 4 weeks. We observed a 1.4-fold increase (p < 0.05) in pulmonary macrophage content as measured by F4/80 IHC (Fig. 5A) . Furthermore, we measured levels of the inflammatory markers P-NFkB and IL-17A and the estrogen response gene vascular endothelial growth factor gene (VEGF). We observed a signficant increase in P-NFkB high-grade staining (40% [10 of 25 fields], p < 0.001 [ Fig. 5B] ) and VEGF high-grade staining (44% [14 of 32 fields], p<0.001 [ Fig. 5C ]) in lung preneoplasias that developed after tobacco carcinogen and E2 exposure in mice compared with in the control (0% highgrade staining for each marker). Similar results were observed in normal bronchial epithelium in reponse to E2 (not shown). Furthermore, IL-17A expression was also increased in lung preneoplasias by E2 treatment in this animal model, with 28% high-scoring fields in the control group compared with 60% in the E2 group (p ¼ 0.06) (Fig. 5D ). These changes were accompanied by a 1.3-fold increase in blood vessel formation with estrogen treatment (data not shown). Finally, although the levels were very low, we observed a 3-fold increase in circulating levels of IL-17A in the mice treated with E2 (17.0 pg/mL [range 7.2-48.8 pg/mL]) compared with the control (5.7 pg/mL [range 5.4-6.2 pg/mL]). Ki67 proliferative index was also signficantly increased (p < 0.001) in preneoplasias by E2 exposure (data not shown).
Discussion
More than 80% of human NSCLC lung tumors of all histological types are positive for ERs, and we and others have shown that estrogen is a driver of NSCLC proliferation in vitro and in vivo (reviewed in Burns and Stabile 26 ). More than 60% of human lung tumors of different histological types are also are positive for aromatase expression, either in the carcinoma cells themselves, in tumor-associated macrophages, or in the tumor stroma. 3, 5, 27 Additionally, high expression of tissue aromatase is a poor prognostic marker in menopausal women with NSCLC. 5 There are limited studies evaluating the effect of AIs in lung cancer. Preclinically, exemestane has been shown to inhibit migration and invasion in NSCLC cell lines in vitro accompanied by changes in cell morphology, 28 and it dramatically reduced lung tumor xenograft growth, especially when combined with standard chemotherapy. 11 Moreover, we have shown previously that anastrozole alone reduced the number of tobacco-induced lung tumors in mice by approximately 40%, both when given during NNK exposure and when given after NNK exposure. 13 These preclinical AI studies, along with evidence identifying estrogen as a driver of lung tumorigenesis, have led to two ongoing clinical trials with AIs for lung cancer in the metastatic setting, including a phase I trial of exemestane in combination with chemotherapy (NCT01664754) and a phase II single-agent exemestane study (NCT02666105).
In breast cancer, a causal link between inflammation and E2 has been established. In this regard, triggers of inflammation, such as obesity, increase E2 production in the mammary microenvironment through the combined action of macrophages and adipocytes driven by the cytokines and growth factors released at the site of inflammation that increase tissue aromatase expression. 29 This local E2 production through the action of tissue aromatase increases the risk for breast cancer development. Thus, AIs are now the standard of care for treatment of hormone receptor-positive breast cancer, both in the adjuvant setting and in advanced disease, 30, 31 and they are also considered as a chemoprevention option for women at high-risk for development of breast cancer. 32, 33 Similarly in lung cancer, tobacco carcinogens produce an inflammatory response that causes an influx of macrophages into the lungs, with stimulation of cytokine production. Our previous studies in both animal models and human tumor tissue provide evidence that the lung microenvironment is a site of local E2 synthesis through the action of tissue aromatase. Thus, a similar link between inflammation and E2 production in the tumor microenvironment also plays a role in development of lung cancer.
Confirming the association between E2 and inflammation, use of anti-inflammatory drugs has been shown to reduce E2 levels in postmenopausal women 23, 24 and has been associated with decreased risk for hormonedriven cancers such as breast and ovarian cancer. 34 Use of an NSAID such as aspirin was associated with lower circulating E2, and mechanistic studies suggest that aspirin has a direct effect of reducing aromatase expression by inhibiting COX2 expression and prostaglandin synthesis. 35 The combination of the antiinflammatory agent celecoxib with the AI exemestane reduced E2 levels and protumor biomarkers such as Ki67 in postmenopausal women with ductal carcinoma in situ compared with single treatment. 36 Thus, reducing aromatase expression by means of an NSAID and inhibiting tissue aromatase activity with an AI may be an effective strategy to reduce E2 levels, thereby inhibiting the proliferative effects of E2. COX2 inhibition itself also results in a decrease in VEGF, IL-6, and IL-8 and is associated with decreased angiogenesis, decreased resistance to apoptosis, and increased antitumor cellular immunity. [37] [38] [39] These effects should also contribute independently to cancer prevention and add to effects on the estrogen pathway. In this article, we sought evidence that such a strategy would be effective for lung cancer prevention by using a carcinogen-induced murine lung tumor model.
Using our well-characterized NNK lung tumor model in which tissue aromatase expression and E2 production is increased at inflammatory sites with NNK exposure, 13 our results show that the AI anastrozole maximally prevents lung tumor development after carcinogen exposure when combined with an NSAID. Effects were observed with both aspirin and ibuprofen. The mean number of lung tumors per mouse and tumor size were lower with combined anastrozole and NSAID treatment after exposure to tobacco carcinogen. These combination effects were accompanied by lower levels of circulating E2, as well as by a change in the inflammatory environment and proliferative and signaling capacity of the tumors with all end points examined, compared with controls. Examining all inflammatory and proliferative end points together as a group, individual treatments modulated some but not all end points compared with vehicle control, whereas with combination treatment all end points were significantly different from those with vehicle. This finding strongly suggests that combining an AI with an NSAID will produce a greater preventive effect against lung tumor formation. Decreased estrogen-mediated 
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Aromatase Inhibitors, NSAIDs, and Lung Cancercross talk with growth factor signaling pathways that leads to decreased MAPK and STAT3 activation may contribute to the lower proliferative rate, in addition to downstream signaling from the ER itself. Of the panel of cytokines that we examined in the circulating blood, only IL-6 had levels that differed significantly by treatment group. Increased systemic and pulmonary production of IL-6 is commonly observed in patients with lung adenocarcinoma and correlates with poor patient survival. [40] [41] [42] [43] IL-6 is a pleotropic cytokine that is considered a biomarker of ongoing inflammation with potential to modulate the immune response. This effect was observed not only after 8 weeks of AI and/or NSAID treatment, but also after only 2 weeks of treatment in our short-term exposure experiment. Furthermore, we observed that tumoral IL-17A expression and macrophage content was down-regulated by both anastrozole and aspirin treatments. IL-17A is a proinflammatory cytokine produced by both Th-17 cells and macrophages. High levels of IL-17A expression are also associated with poor survival in patients with lung cancer. 44 IL-17A has also been linked to lung tumor progression 45, 46 and initiates an inflammatory response (including recruitment of macrophages and neutrophils) by inducing production of other cytokines such as IL-6.
47
IL-17A is also thought to promote epithelialmesenchymal transition in lung cancer and can also promote tumor growth through the IL-6/STAT3 signaling pathway. A recent study found that patients with lung cancer with both increased IL-6 and increased IL-17A had significantly worse survival than did patients with low levels of these cytokines or high levels of only one of these cytokines. 48 Both IL-6 and IL-17A can be tumor derived or released from tumor-associated macrophages. Together, the decreases observed in IL-17A, IL-6, and macrophage recruitment suggest a role for E2-driven regulation of the inflammatory environment in the lung. Furthermore, down-regulating the lung stem cell phenotype may be an important part of this combined effect, as we observed significant downregulation of Sox-2 expression in the lungs (both in the bronchial epithelium and in preneoplasias) of mice treated with anastrozole or aspirin. This is consistent with our previous observation that both Sox-2 and Nanog expression were decreased with anastrozole treatment and were positively correlated. 22 A novel role of ERb and estrogen sensitivity in breast cancer stem cells that may contribute to the importance of estrogens for tumor growth has recently been described. 49 Our results are in agreement with those of other studies demonstrating a link between Akt signaling through the IL-6/STAT3 axis to maintaining stemness, and this signaling axis is highly active in cancer stem cells. 50, 51 Preneoplasias also had reduced VEGF-A expression after anastrozole and combination treatment, in accordance with inhibition of E2-mediated pathways. Because IL-6 is also known to promote the release of VEGF to regulate tumor angiogenesis, the overall effect of reduction in IL-6 by anastrozole, aspirin, or their combination could be directly driving reduction in the VEGF/angiogenesis pathway, contributing to the overall chemoprevention effect. [52] [53] [54] We also showed the opposite effect on the inflammatory microenvironment when we used male mice treated with NNK and E2. In this model, a 4-week exposure was used to simulate the inflammatory environment that is present in smokers before tumors develop. We found increased macrophage content and increased inflammatory markers such as VEGF and p-NFkB in lung tissue. These results confirm our previous studies in NSCLC cell lines in which E2 induced VEGF-A mRNA and protein secretion and combining an antiestrogen with a VEGFR inhibitor showed enhanced antitumorigenic effects in a NSCLC xenograft model. 55 VEGF has also been shown to induce macrophage recruitment and regulate the M1 to M2 macrophage phenotypic switch. 56 Previous studies have also shown that the tumor-promoting immunosuppressive M2 phenotype is also promoted by E2. 14 The exact mechanism of macrophage infiltration from E2 exposure is still unclear but may be partly responsible for estrogen-driven tumorigenesis of the lung. These findings provide a new perspective on the effects of estrogen in the lung tumor microenvironment by increasing macrophage production and proinflammatory markers to drive proliferation, in addition to direct stimulation of ER-positive pulmonary epithelial cells. The role that estrogens play in proinflammatory versus anti-inflammatory activities appears to be disease-state dependent, with estrogeninduced anti-inflammatory effects identified in bone remodeling, CNS conditions, and autoimmune disorders. [57] [58] [59] This may be due to selective actions of E2 on specific immune cell types in different organs. It is clear that the inflammatory milieu, although complex in nature, plays a critical role in the lung carcinogenic process. Further studies examining the effects of E2 inhibition on different immune cell types in the lung microenvironment are needed to fully understand the overall effect of targeting estrogen on lung tumorigenesis.
In conclusion, our results suggest that the combination of low-dose NSAID with an AI may reduce cancer risk in postmenopausal women who are at increased risk for lung cancer. Women at high-risk for breast cancer may also benefit from this combination treatment approach, as low-dose aspirin alone has been shown to reduce risk for hormone receptor-positive breast cancer development by 20%. 60 This strategy for lung cancer chemoprevention would be particularly effective in postmenopausal women who have inflammatory lung diseases such as chronic obstructive pulmonary disease. Furthermore, this combination would be an inexpensive and well-tolerated preventive measure that could be easily implemented in clinical practice. Future studies to delineate the mechanism of estrogen-mediated immune and inflammatory modulation in the lung tumor microenvironment are necessary.
